NCT06066359 2026-03-11
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT06518551 2025-12-11
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT07075510 2025-10-29
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
University of Maryland, Baltimore
Phase 1/2 Recruiting
NCT07032129 2025-06-22
BAH2573
Essen Biotech
Phase 1/2 Recruiting
NCT04271644 2025-02-25
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Recruiting
NCT04776330 2025-02-25
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Recruiting
NCT06644443 2024-10-16
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT04879043 2024-07-24
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Heidelberg Pharma AG
Phase 1/2 Recruiting
NCT06132711 2023-11-15
CAR-T
Xuzhou Medical University
Phase 1/2 Recruiting
NCT05573802 2023-10-24
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
Phase 1/2 Recruiting